I just joined seekingAlpha and tried to get the following comment on your post in, but have failed While I haven't read all 144 comments, few people commenting here appear to be clinicians who have actually taken care of Alzheimer patients. Therefore it

I just joined seekingAlpha and tried to get the following comment on your post in, but have failed.  It was in response to the post by C. C. Abbott who wrote back and encouraged me to comment again. 

While I haven't read all 144 comments, few people commenting here appear to be clinicians who have actually taken care of Alzheimer patients. Therefore it is improbable that the commenters would have seen what is so significant about the Cassava 1 year data on 50 patients with early Alzheimer's. In fact, I think that Cassava missed it themselves.

It's simply this -- of the 50 patients completing 1 year, 5 had a nearly 50% improvement in their ADAS-Cog score. This is incredible, and unheard of in Alzheimer's disease. It doesn't matter what the averages are or whether the data have cherry picked. If the results are in fact true, nothing like this has ever been seen in Alzheimer's disease. I certainly didn't see it in 33 years of clinical neurology and probably well over 300 patients. I can recall 1 or 2 who weren't worse after a year, but not one was better.

There is a lot more detail and links to the 1 year data in a blog that I write -- luysii.wordpress.com/2021/08/25/cassava-.../